Summary:
- The article discusses the early data on the use of TCE (Tofacitinib, Cyclophosphamide, and Efalizumab) therapy for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease.
- The TCE therapy has shown promising results in a small pilot study, with patients experiencing quick responses and improvements in their SLE symptoms.
- The article highlights the potential of this combination therapy as a new approach to managing SLE, which is often a challenging condition to treat effectively.